The experimental results obtained with the new allergoids conjugated with mannan administered sublingually have been published in Allergy.
These glycoconjugates, which have been designed to target dendritic cells, are better captured by the antigen-presenting cells from the oral mucosa. Moreover, the immunomodulating properties ascribed to these glycoconjugates are preserved when administering through this route.
This new research shows the advantages of these glycoconjugates in comparison with conventional allergens for sublingual immunotherapy. Their lower allergenicity, greater uptake by dendritic cells and availability for inducing tolerogenic responses, makes them good candidates for a new generation of vaccines against allergic diseases.